Anti-tumor effects after adoptive transfer of IL-12 transposon-modified murine splenocytes in the OT-i-melanoma mouse model

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Galvan, Daniel L ^a   O'Neil, Richard T ^d   Foster, Aaron E ^a   Huye, Leslie ^a,b   Bear, Adham ^a   Rooney, Cliona M ^a,b   Wilson, Matthew H ^a,c,d  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; OVALBUMIN; TRANSPOSON;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TRANSPOSON; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; NEOPLASMS, EXPERIMENTAL; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SPLEEN; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; DNA TRANSPOSABLE ELEMENTS; HELA CELLS; HUMANS; INTERLEUKIN-12; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTES;

EID: 84948986254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140744     Document Type: Article

References (45)

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003; 3(9):666-75.
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308.
3. Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev. 2014; 257(1):145-64.
4. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010; 18(4):674-83.
5. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68(8):2961-71. doi: 10.1158/0008-5472.CAN-07-5600 PMID: 18413766
6. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014; 257(1):181-90.
7. Vandendriessche T, Ivics Z, Izsvak Z, Chuah MK. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood. 2009; 114(8):1461-8. doi: 10.1182/blood-2009-04-210427 PMID: 19471016
8. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH. Hyperactive piggyBac Gene Transfer in Human Cells and In Vivo. Human Gene Therapy. 2012; 23(3):311-20. doi: 10.1089/hum.2011.138 PMID: 21992617
9. Yusa K, Zhou L, Li MA, Bradley A, Craig NL. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci USA. 2011; 108(4):1531-6.
10. Li MA, Turner DJ, Ning Z, Yusa K, Liang Q, Eckert S, et al. Mobilization of giant piggyBac transposons in the mouse genome. Nucleic Acids Res. 2011; 39(22):e148. doi: 10.1093/nar/gkr764 PMID: 21948799
11. Kahlig KM, Saridey SK, Kaja A, Daniels MA, George AL Jr., Wilson MH. Multiplexed transposon-medi-ated stable gene transfer in human cells. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(4):1343-8. doi: 10.1073/pnas.0910383107 PMID: 20080581
12. Fraser MJ, Ciszczon T, Elick T, Bauser C. Precise excision ofTTAA-specificlepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol Biol. 1996; 5(2):141-51.
13. Wilson MH, Coates CJ, George AL Jr. Piggy Bac transposon-mediated gene transfer in human cells. Molecular Therapy. 2007; 15(1):139-45. PMID: 17164785
14. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, et al. Evaluation of Long-term Trans-gene Expression in piggyBac-Modified Human T Lymphocytes. Journal of Immunotherapy. 2013; 36 (1):3-10. doi: 10.1097/CJI.0b013e3182791234 PMID: 23211626
15. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, et al. piggyBactransposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010; 21(4):427-37.
16. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, et al. Optimization of the Piggy Bac transposon system for the sustained genetic modification of human T lymphocytes. JImmunother. 2009; 32(8):826-36.
17. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, et al. Piggy Bac-mediatedcancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011; 19(12):2133-43.
18. Goffinet C, Keppler OT. Efficient nonviral gene delivery into primary lymphocytes from rats and mice. FASEB J. 2006; 20(3):500-2. PMID: 16401643
19. Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovic D, et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. JImmunol. 2005; 174(9):5766-73.
20. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, et al. T cells compete for access to antigen-bearing antigen-presenting cells. JExp Med. 2000; 192(8):1105-13.
21. Song XT, Turnis ME, Zhou X, Zhu W, Hong BX, Rollins L, et al. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011; 19(1):211-7.
22. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. JClin Oncol. 2005; 23(10):2346-57.
23. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. JClin Oncol. 2008; 26(32):5233-9.
24. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMID: 16946036
25. Gately MK. Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest. 1993; 11(4):500-6. PMID: 8100734
26. Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP. Effects of IL-12 on the generation of cytotoxic activity in human CD8+T lymphocytes. JImmunol. 1993; 151(5):2444-52.
27. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res. 2012; 18(6):1672-83.
28. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther. 2001; 12(6):671-84.
29. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. JImmunol. 1995; 155(3):1393-403.
30. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporationforthe successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002; 5(6):668-75.
31. Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG. Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig. 1998; 6(2):71-80.
32. Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, et al. Hema Max, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 2012; 7(2):e30434.
33. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011; 19(4):751-9.
34. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, et al. Evaluation of long-term trans-gene expression in piggyBac-modified human T lymphocytes. JImmunother. 2013; 36(1):3-10.
35. Wilson MH, Coates CJ, George AL Jr. Piggy Bac Transposon-mediated Gene Transfer in Human Cells. Mol Ther. 2007; 15(1):139-45.
36. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNAtransposons in gene therapy. Transl Res. 2013; 161(4):265-83.
37. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays. 2010; 32(9):756-67. doi: 10.1002/bies.201000027 PMID: 20652893
38. Atkins MB, Robertson MJ, Gordon M, Lotze MT, De Coste M, Du Bois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997; 3(3):409-17.
39. Gollob JA, Mier JW, Atkins MB. Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Re-sponse Modif. 2001; 19:353-69.
40. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90(7):2541-8. PMID: 9326219
41. Daud AI, De Conti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. JClin Oncol. 2008; 26(36):5896-903.
42. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumor-specific CD8+T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010; 70(17):6725-34. doi: 10.1158/0008-5472.CAN-10-0735 PMID: 20647327
43. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. JExp Med. 1998; 188(2):277-86.
44. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127 PMID: 25212991
45. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015; 33:9-15. doi: 10.1016/j.coi.2015.01.002 PMID: 25621840